Generative AI in MedTech: A Quality Transformation Case Study

Generative AI in MedTech becomes valuable when it is attached to a specific evidence flow, a measurable bottleneck, and an accountable regulated decision. The following composite case study reflects patterns seen across global diagnostic-equipment manufacturers, with details and metrics synthesized to protect company confidentiality. It follows a manufacturer that used generative AI to improve complaint investigation and feed recurring field evidence back into CAPA, supplier quality, and design assurance.

The program illustrates how Generative AI in MedTech can support post-market surveillance without allowing a probabilistic model to become the reportability decision maker. Its results came from controlled retrieval, product-specific evaluation, and workflow redesign—not from prompt engineering alone. The lessons apply to manufacturers managing complex portfolios similar in scale to those of Siemens Healthineers, GE HealthCare, Abbott, or Medtronic.

The Case: A Growing Complaint Backlog Across a Diagnostic Portfolio

Arboris Diagnostics, a fictionalized manufacturer, sold 14 analyzer platforms and approximately 180 reagent, accessory, and software configurations in 37 markets. Its quality organization received 96,000 complaint records annually from customer support, distributors, field service engineering, and vigilance teams. Volume had increased 31 percent in two years, while the number of experienced complaint investigators had grown only 8 percent. Median time from intake to initial reportability assessment had reached 3.8 business days.

The underlying process crossed six systems. Customer-support narratives entered a CRM; installed-base and UDI data lived in a service platform; device history and lot information came from manufacturing systems; controlled procedures resided in the electronic QMS; risk files and design records were managed separately; and prior investigations existed as attachments in the complaint system. Investigators routinely spent 24 to 35 minutes locating and reconciling records before conducting the substantive assessment.

The consequences extended beyond queue length. Similar failure descriptions were coded inconsistently, delaying adverse-event signal detection. Supplier-related trends were discovered through monthly manual reviews rather than near-real-time surveillance. Approximately 17 percent of cases were returned for missing information, and CAPA owners complained that complaint summaries lacked enough technical detail to support root-cause analysis. Regulatory affairs also saw variation in reportability rationales across regions.

Leadership established three non-negotiable goals: cut median intake-to-assessment time by at least 30 percent, improve coding consistency without reducing sensitivity to potentially reportable events, and generate traceable summaries that investigators could verify in under five minutes. The model would recommend and draft, but trained personnel would retain responsibility for complaint classification, investigation adequacy, and medical device reporting decisions.

Designing the Generative AI in MedTech Workflow

From free text to an evidence-backed case package

The team decomposed the workflow into bounded capabilities. First, the system extracted device identity, event date, alleged malfunction, patient involvement, clinical outcome, service actions, error codes, and missing information from the intake narrative. Second, it reconciled product references against UDI and installed-base records. Third, it retrieved approved complaint codes, relevant risk-file entries, similar closed cases, and current procedures. Finally, it drafted a structured synopsis and proposed questions for follow-up.

Every generated field displayed its source passage. When device identity could not be resolved, the workflow stopped and requested human clarification. If the narrative mentioned death, serious injury, intervention, delayed diagnosis, cybersecurity compromise, or an unfamiliar malfunction, the case entered an expedited queue regardless of model confidence. The system was prohibited from submitting a vigilance report, closing a complaint, modifying a risk file, or initiating CAPA autonomously.

Establishing an authoritative product and document layer

The most difficult engineering work was not model selection. Product names used by customers differed from names in the device master record, and field engineers frequently referenced informal module abbreviations. The project team created a governed identity map linking commercial names, catalog numbers, serial-number patterns, software versions, accessories, and UDI device identifiers. Supplier part numbers were mapped only when approved relationships existed.

Controlled-document retrieval was restricted by status, product family, geography, and effective date. Obsolete work instructions remained searchable for historical investigations but were clearly labeled and could not support a current procedural recommendation. Each retrieved passage carried the document identifier, revision, approval status, and effective period. This foundation reduced the risk that Generative AI in MedTech would merge evidence from incompatible configurations.

Governance and functional ownership

Quality management owned the intended use and production release. Post-market surveillance defined escalation rules and signal-detection requirements. Regulatory affairs approved the reportability-support boundary, while medical affairs reviewed clinical terminology and harm categories. Field service engineering validated error-code interpretation, supplier quality reviewed component mappings, and privacy and cybersecurity teams established access, logging, retention, and threat controls.

A design assurance representative participated even though the assistant was an internal quality tool. Complaint trends can lead to risk-management updates, design changes, or new verification activities, so maintaining clean evidence lineage mattered. The governance board required that any generated content transferred into a controlled record retain its sources, reviewer identity, model-system version, and timestamp.

Validation Strategy and Release Criteria

The validation set contained 6,400 historical complaints sampled across all 14 platforms, four regions, and three years. It deliberately overrepresented serious injuries, deaths, rare malfunctions, cybersecurity allegations, incomplete narratives, translated text, and device-identity ambiguity. Another 1,200 cases were held back for final testing. No case used for prompt development or taxonomy mapping appeared in the holdout set.

The team evaluated the complete system rather than the language model alone. Tests covered document ingestion, table parsing, identity resolution, retrieval, prompt templates, access permissions, output rendering, audit logs, and escalation routing. Red-team scenarios placed malicious instructions in attachments, attempted cross-product data access, and used plausible but nonexistent error codes. Performance was measured by field-level extraction, evidence support, coding agreement, critical-event sensitivity, and reviewer effort.

• Critical-event escalation sensitivity had to be at least 99.5 percent, with every miss formally reviewed.
• Device-identity resolution needed 97 percent precision; ambiguous identities had to trigger abstention.
• At least 98 percent of factual statements in generated summaries required direct source support.
• Suggested complaint codes needed 90 percent top-three agreement with an expert adjudication panel.
• Median expert verification time had to remain below five minutes.

Initial testing failed two release criteria. Critical-event sensitivity was 98.7 percent because indirect descriptions of clinical intervention were missed, and identity precision fell on accessories shared across product families. The team did not solve these defects by instructing the model to be more careful. It expanded the clinical phrase taxonomy, introduced deterministic escalation rules, corrected product mappings, and required serial-number confirmation for shared accessories. The second test reached 99.7 percent escalation sensitivity and 97.8 percent identity precision.

Human factors and reviewer calibration

Twenty-four investigators participated in simulated-use testing. Early interface designs displayed a polished narrative first, which encouraged reviewers to accept the framing before inspecting evidence. The revised interface presented extracted facts and source passages before the draft synopsis. It also separated observed facts, system inferences, and unresolved questions. Reviewers completed calibration exercises on borderline cases, with disagreements adjudicated by post-market surveillance and regulatory affairs.

This change mattered because automation bias is a workflow hazard, not merely a training issue. Reviewers needed an efficient way to challenge a suggestion and document why. Overrides were categorized so the production team could distinguish model error, missing source data, taxonomy gaps, procedural ambiguity, and legitimate expert judgment.

Six-Month Results and the Decisions Behind Them

The manufacturer released the system to two product families, monitored it for eight weeks, and then expanded in four controlled waves. At six months, 38,700 complaints had passed through the assisted workflow. Median time from intake to initial assessment fell from 3.8 to 2.1 business days, a 45 percent reduction. Median investigator preparation time dropped from 29 minutes to 11 minutes. The percentage of cases returned for missing information declined from 17 percent to 9 percent because follow-up questions were generated at intake.

Coding consistency improved as well. Agreement between the first investigator and expert quality review rose from 82 percent to 94 percent for the ten highest-volume malfunction categories. The system escalated 100 percent of confirmed serious-event cases during the period, although human reviewers overrode 4.6 percent of proposed severity classifications. Importantly, those overrides remained visible and became inputs to monthly performance review.

The project did not reduce headcount. Instead, the complaint unit reassigned approximately 5,600 specialist hours over six months from record assembly to investigation, trend review, and overdue-case reduction. The open complaint backlog declined 52 percent, while the proportion of cases receiving engineering evaluation within the target period increased from 71 percent to 91 percent. These metrics made the operational value of Generative AI in MedTech concrete without treating automated output volume as success.

Earlier supplier and CAPA signals

A mid-body expansion connected complaint clusters with field service actions and supplier lot data. Because this required multi-step retrieval and controlled routing, the manufacturer engaged specialists in AI agent engineering to design an agent that could gather evidence but not alter QMS records. When thresholds were met, it created a draft signal packet for post-market surveillance review.

One cluster involved intermittent optical calibration failures across two analyzer models. The assistant connected differently worded complaints, recurring service replacement of the same module, and a supplier process-change period. Signal review began 19 days earlier than it would have under the prior monthly process. Supplier quality traced the issue to coating-thickness variability, quarantined affected inventory, and initiated a supplier corrective action. A related CAPA added incoming inspection criteria and revised process controls.

The investigation demonstrated both value and limitation. The AI assembled a credible pattern, but it could not establish root cause. Manufacturing engineering, supplier quality, and research and product development still conducted measurement-system analysis, component testing, and failure reproduction. Design assurance assessed whether risk controls and verification evidence remained adequate. The model accelerated evidence discovery; it did not replace engineering judgment.

Lessons for Scaling MedTech AI Solutions

Lesson one: improve the evidence architecture before expanding autonomy

The identity map and controlled-document layer delivered value beyond the original use case. They later supported AI for Regulatory Affairs by helping authors locate approved complaint trends and risk evidence for periodic reports. They also enabled a limited Medical Device Design AI workflow that compared post-market findings with design inputs and risk controls. Neither extension would have been defensible if product identity and document authority remained unresolved.

The company therefore treated retrieval content, terminology mappings, and product relationships as governed configuration items. Owners reviewed changes, impact was assessed, and regression tests ran before production release. This discipline prevented a seemingly minor taxonomy edit from silently changing complaint clustering across the portfolio.

Lesson two: connect monitoring to the QMS

The production dashboard tracked unsupported statements, abstention, overrides, critical escalations, retrieval failures, reviewer time, and variation by product family. Monthly review identified a gradual increase in abstention after a software upgrade introduced new error codes. The issue was corrected through device taxonomy updates, then verified against recent cases. No model retraining was required.

More serious failures followed the existing nonconformance and CAPA framework. The procedure defined when an isolated output error required correction, when a broader impact assessment was necessary, and when recurrence or systemic weakness justified CAPA. Effectiveness checks used representative cases and production monitoring rather than confirming that a prompt edit had been installed. This made AI-Powered Quality Management part of the QMS instead of a parallel technology process.

Lesson three: scale by reusable controls, not copied pilots

After the complaint deployment, the manufacturer created a common control library for MedTech AI Solutions. It covered intended-use templates, risk tiers, data classification, human oversight, source citations, access controls, evaluation design, change management, incident response, and retirement. New teams could reuse these controls while adding process-specific hazards and acceptance criteria.

The regulatory drafting pilot, for example, reused authentication and evidence-lineage controls but required different evaluation. Its critical tests focused on claim consistency, correct market context, accurate document revision, and unsupported regulatory assertions. The design-control pilot emphasized linkage among user needs, design inputs, risk controls, and verification evidence. Reuse accelerated deployment without pretending that one validation package could cover every use case.

Lesson four: measure quality alongside speed

The program would have looked successful if it measured only the 62 percent reduction in preparation time. Its stronger case came from paired measures: escalation sensitivity, coding agreement, missing-information rates, override patterns, backlog, and engineering-review timeliness. These indicators showed whether efficiency gains shifted risk downstream. They also gave quality leadership a basis for deciding when to pause expansion.

Over time, the team added leading indicators such as retrieval failure by document type and the proportion of recommendations based on a single source. These measures detected weakening evidence conditions before they appeared as incorrect controlled records. That monitoring approach is central to sustainable Generative AI in MedTech because model behavior and source data can change independently.

Conclusion

This case shows that Generative AI in MedTech can materially improve complaint handling, signal surveillance, and CAPA inputs when the manufacturer constrains intended use and validates the complete workflow. The 45 percent cycle-time reduction mattered, but the more durable achievements were evidence traceability, stronger coding consistency, earlier supplier signals, and preserved human authority over regulated decisions. Organizations evaluating MedTech AI Solutions should begin with a measurable bottleneck, build authoritative data relationships, test rare high-severity conditions, and expand only when production evidence confirms that speed and quality are improving together.